Login to Your Account

Other news to note

Wednesday, July 30, 2014

Retrophin Inc., of New York, said it submitted a proposal to the board of Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 (US$2.04) per share in cash.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription